third-generation recombinant protective antigen program (Altimmune)

N/A

Report date: 2025/03/19 11:41:42

Base Information

Drug Namethird-generation recombinant protective antigen program (Altimmune)
Drug Alias Namethird-generation rPA (Avecia)third-generation recombinant protective antigen program (PharmAthene)third-generation recombinant protective antigen (Avecia)third-generation recombinant protective antigen program (Avecia)third-generation anthrax vaccine (Avecia)
ClassificationVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineBiologics > Protein drugs > Recombinant proteinVaccines > Application > Prophylactic vaccine
Mechanisms of ActionAnthrax protective antigen modulators
TargetsAnthrax protective antigen
Therapy Area/IndicationsAnthrax
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomIsrael
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFujifilm Diosynth Biotechnologies UK Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAltimmune IncMedison Pharma Ltd
Inactive CompaniesPharmathene IncFujifilm Diosynth Biotechnologies UK Ltd
Active IndicationsAnthrax
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A